Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method

Area of Science:

• Neuroscience
• Biochemistry
• Clinical Chemistry

Background:

• Catecholamines and indolealkylamines are crucial in neurological and psychiatric disorders.
• Measuring these compounds in cerebrospinal fluid (CSF) aids diagnosis and treatment monitoring.
• Existing methods may be complex, costly, or time-consuming.

Purpose of the Study:

• To develop and validate a simple, sensitive, rapid, and inexpensive method for measuring specific catecholamine and indolealkylamine metabolites in human CSF.
• To investigate the utility of this method in differentiating neurological and psychiatric conditions.

Main Methods:

• High-performance liquid chromatography (HPLC) coupled with an electrochemical detector (ECD).
• Measurement of 3-methoxy-DOPA, 3-methoxy-4-hydroxyphenylglycol, dihydroxyphenylacetic acid, tryptophan, 5-hydroxyindoleacetic acid, and homovanillic acid in human CSF.
• Analysis of patient samples from Parkinson's disease, depression, and subarachnoid hemorrhage cohorts.

Main Results:

• Parkinson's disease patients showed decreased homovanillic acid, which normalized with L-3,4-dihydroxyphenylalanine treatment, and increased 3-methoxy-DOPA.
• Depression was associated with reduced serotonin turnover (lower 5-hydroxyindoleacetic acid) and decreased tryptophan levels.
• Subarachnoid hemorrhage patients exhibited augmented monoamine metabolite levels.

Conclusions:

• The developed HPLC-ECD method is effective for quantifying key monoamine metabolites in human CSF.
• CSF levels of these metabolites can serve as biomarkers for Parkinson's disease, depression, and subarachnoid hemorrhage.
• This assay provides a valuable tool for clinical diagnostics and research in neurological and psychiatric disorders.